---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-025201"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T17:52:41.282220+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Voyager Q4 2025 net loss $27.4M, cash $201.7M; key pipeline milestones H2 2026

## Summary
- Q4 2025 net loss $27.4M vs $34.5M in Q4 2024; full year net loss $119.7M vs $65.0M.
- Collaboration revenue Q4 $15.3M (up 143% YoY) but full year $40.4M (down 50% YoY).
- Cash $201.7M at Dec 31 2025; runway expected into 2028 with up to $2.4B in milestone potential.
- VY1706 (tau-silencing) IND planned Q2 2026, first-in-human dosing H2 2026; VY7523 tau PET data H2 2026.
- APOE gene therapy program paused; Neurocrine milestone $3M triggered in Q4 2025.

## SEC filing metadata
- accession: 0001104659-26-025201
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000110465926025201/0001104659-26-025201-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000110465926025201/vygr-20260309x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-025201
- JSON: https://secwatch.observer/filing/0001104659-26-025201.json
- Plain text: https://secwatch.observer/filing/0001104659-26-025201.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.